Common use of EFFECTIVE AND BINDING AGREEMENT Clause in Contracts

EFFECTIVE AND BINDING AGREEMENT. Biovail and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of Biovail; B. This CIA shall become final and binding on the date the final signature is obtained on the CIA; C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA; D. The undersigned Biovail signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatory represents that he is signing this CIA in his official capacity and that he is authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /s/ Xxxxxxxx Xxxxxxx September 11, 2009 Xxxxxxxx Xxxxxxx DATE Vice President, Associate General Counsel Biovail Corporation /s/ Xxxxxxxx X. Xxxxxx 9/11/09 Xxxxxxxx X. Xxxxxx DATE Xxxxxxxxx & Xxxxxxx LLP Counsel for Biovail Corporation /s/ Xxxxxxx X. Xxxxxx 9/11/09 XXXXXXX X. XXXXXX DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Biovail Consistent with the provisions in the Settlement Agreement pursuant to which this CIA is entered, InterMune and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of BiovailInterMune; B. This CIA shall become final and binding on the date the final signature is obtained on the CIA; C. This Any modifications to this CIA constitutes shall be made with the complete agreement between the parties and may not be amended except by prior written consent of the parties to this CIA; D. The undersigned Biovail InterMune signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatory represents that he is signing this CIA in his official capacity and that he is authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /s/ Xxxxxxxx Xxxxxxx September 11, 2009 Xxxxxxxx Xxxxxxx DATE RXXXX XXXXXX Rxxxx Xxxxxx Date Senior Vice President, Associate President and General Counsel Biovail Corporation InterMune, Inc. /s/ Xxxxxxxx MXXXXXX XXXXX Mxxxxxx XxXxx Date Compliance Officer InterMune, Inc. /s/ EXXXX XXXXXX Exxxx Xxxxxx, Esq. Date Counsel for InterMune, Inc. /s/ GXXXXXX X. XXXXXX Gxxxxxx X. Xxxxxx 9/11/09 Xxxxxxxx X. Xxxxxx DATE Xxxxxxxxx & Xxxxxxx LLP Counsel for Biovail Corporation /s/ Xxxxxxx X. Xxxxxx 9/11/09 XXXXXXX X. XXXXXX DATE Date Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.D of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Biovail Daiichi and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of Biovail; B. This CIA shall become final and binding on the date the final signature is obtained on the CIA;. C. B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA;. D. C. The undersigned Biovail Daiichi signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatory represents signatories represent that he is they are signing this CIA in his their official capacity and that he is they are authorized to execute this CIA. E. D. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /s/ Xxxxxxxx /Xxxxxx Xxxxxxx September 11Xxxxxx/ 1-6-15 XXXXXX XXXXXXX XXXXXX DATE PRESIDENT, 2009 Xxxxxxxx Xxxxxxx U.S. COMMERCIAL DAIICHI SANKYO, INC. /Xxxxx Xxxxxxxxx/ 1-7-15 XXXXX XXXXXXXXX DATE Vice President, Associate General Counsel Biovail Corporation /s/ Xxxxxxxx X. Xxxxxx 9/11/09 Xxxxxxxx X. Xxxxxx DATE Xxxxxxxxx & Xxxxxxx LLP Counsel for Biovail Corporation /s/ Xxxxxxx Daiichi /Xxxxxx X. Xxxxxx 9/11/09 XxXxxxx/ 1/7/15 XXXXXX X. XXXXXXX X. XXXXXX DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. U. S. Department of Health and Human Services /Xxxxxx X. Xxxxxxxx/ 1/7/15 XXXXXX X. XXXXXXXX DATE Senior Counsel Office of Inspector General U. S. Department of Health and Human Services This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.D III.E of the CIA.

EFFECTIVE AND BINDING AGREEMENT. Biovail CCH and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of Biovail; B. This CIA shall become final and binding on the date the final signature is obtained on the CIA; C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA;. D. B. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) CCH’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements. C. The undersigned Biovail CCH signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatory represents signatories represent that he is they are signing this CIA in his their official capacity capacities and that he is they are authorized to execute this CIA. E. D. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles Electronically transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this CIA. /s/ Xxxxxxxx Xxxxxxx September 11/Xxxxxxx X. Xxxx/ 04/30/2024 XXXXXXX X. XXXX DATE President/CEO /Xxxxxxx X. Xxxxx/ 04/30/2024 XXXXXXX X. XXXXX DATE SVP & Chief Legal Officer /Xxxxxxxxx X. Xxxxxx/ 05/10/2024 XXXXXXXXX X. XXXXXX DATE Xxxxxx, 2009 Xxxxxxxx Xxxxxxx DATE Vice President, Associate General Counsel Biovail Corporation /s/ Xxxxxxxx X. Xxxxxx 9/11/09 Xxxxxxxx X. Xxxxxx DATE Xxxxxxxxx Xxxx & Xxxxxxx LLP Counsel for Biovail Corporation /s/ Xxxxxxx X. Xxxxxx 9/11/09 XXXXXXX /Xxxxx Xxxxxx/ 2024.05.14 XXXXX X. XXXXXX DATE Assistant Inspector General for Legal Affairs Office of Inspector General U.S. Department of Health and Human Services /Xxxx X. X’Xxxxx/ 5/14/2024 XXXX X. X’XXXXX DATE Senior Counsel Office of Inspector General U.S. Department of Health and Human Services This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.D of the CIA.